ANNA SHOSTAK: Open Payments
NPI 1447275730 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,400 in 27 payments from 11 companies in 2025. Trend: 2023 $2,019 · 2024 $1,787 · 2025 $2,400
Food & beverage: $2,400
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $729 |
| Otsuka America Pharmaceutical, Inc. | 4 | $413 |
| Axsome Therapeutics, Inc. | 5 | $308 |
| Neurocrine BioSciences, Inc. | 5 | $241 |
| Alkermes, Inc. | 2 | $163 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Lilly USA, LLC | 1 | $125 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
Products named: VRAYLAR, REXULTI, INGREZZA, Auvelity, LYBALVI, UBRELVY, FANAPT, MOUNJARO.
Industry payments across NY — which companies pay providers there.
